Competitive ThreatsCompetitive flow reversal devices for carotid are on the horizon, which could eventually make percutaneous TCAR the 'killer' of open TCAR.
Product PortfolioBoston still has gaps and weaknesses in its vascular portfolio, including areas like aortic and cutting balloons, where markets have commoditized products with equally good alternatives available.
ValuationWith the stock currently trading at 31 times forward twelve-month earnings, well above the 1-, 2-, and 5-year historical multiples more in the 25 times range, this bullish growth outlook is fully reflected in Boston Scientific's valuation.